title: Recombinant human parathyroid hormone therapy (1-34) in an adult patient with a gain-of-function mutation in the calcium-sensing receptor-a case report.
abstract: OBJECTIVE
  To describe a case of hypocalcemia in a patient with a gain-of-function mutation in the calcium-sensing receptor that was undetected until adulthood and successfully treated with recombinant parathyroid hormone.
  
  
  METHODS
  The clinical findings, laboratory data, and a review of the pertinent literature are presented.
  
  
  RESULTS
  A 55-year-old woman was hospitalized and seen by the endocrinology consult service for hypocalcemia that was refractory to repeated doses of intravenous calcium gluconate. She expressed concern about chronic leg muscle cramps and paresthesias of the lips and fingertips. In addition, she had no history of neck surgery, neck irradiation, or any autoimmune disease. She was a well-appearing female with no dysmorphic features or skin changes. Laboratory tests revealed hypocalcemia, hyperphosphatemia, hypomagnesemia, and hypovitaminosis D. Her parathyroid hormone concentration (PTH) was low at 14.2 pg/mL. Her PTH and calcium concentrations remained low despite repletion of magnesium and treatment with calcitriol and oral calcium replacement. A 24-hour collection for urinary calcium showed inappropriate hypercalciuria. Medical records showed her hypocalcemia to be chronic. Additionally, several family members had also complained of muscle cramps. A congenital cause of her hypoparathyroidism was considered, and genetic testing confirmed heterozygosity for a gain-of-function mutation in the calcium-sensing receptor gene associated with autosomal dominant familial isolated hypoparathyroidism (ADH). Treatment with subcutaneous recombinant human parathyroid hormone teriparatide (rhPTH [1-34]) 20 mcg twice daily for three days normalized her calcium and phosphorus concentrations.
  
  
  CONCLUSIONS
  rhPTH (1-34) is an effective treatment for patients with hypoparathyroidism due to gain-of-function mutations in the calcium-sensing receptor. ADH can be insidious in presentation and the diagnosis can be missed unless there is a high index of suspicion.
authors.affiliation: Hattiesburg Clinic, Hattiesburg, MS 39402, USA. mgonzales8232@gmail.com
authors.forename: Michael C
authors.initials: MC
authors.lastname: Gonzales
authors.forename: David C
authors.initials: DC
authors.lastname: Lieb
authors.forename: Donald W
authors.initials: DW
authors.lastname: Richardson
authors.forename: John T
authors.initials: JT
authors.lastname: O'Brian
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Aloi
authors.forename: Romesh K
authors.initials: RK
authors.lastname: Khardori
mesh_terms: D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000235:genetics*; D006996:Hypocalcemia / Q000188:drug therapy* / Q000235:genetics; D007011:Hypoparathyroidism / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D044169:Receptors, Calcium-Sensing / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing